CervoMed Schedule 13G: 750,000 Shares (5.5%)
CervoMed Inc. Schedule 13G filing reports that CVI Investments, Inc. and Heights Capital Management, Inc. together beneficially hold 750,000 shares of CervoMed common stock, representing 5.5% of the class.
Rhea-AI Filing Summary
CervoMed Inc. Schedule 13G filing reports that CVI Investments, Inc. and Heights Capital Management, Inc. together beneficially hold 750,000 shares of CervoMed common stock, representing 5.5% of the class. The filing references 13,526,233 Shares outstanding as of completion of the offering per the Prospectus Supplement dated June 22, 2026. Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and may be deemed to possess voting and dispositive power over the shares; both Reporting Persons disclaim beneficial ownership except for pecuniary interest. The submission is signed by Sarah Travis and includes a Limited Power of Attorney and a Joint Filing Agreement as exhibits.
Positive
- None.
Negative
- None.
Insights
Structured disclosure of beneficial ownership and manager authority.
The filing lists 750,000 shares and states 5.5% of the outstanding common stock, providing a clear ownership snapshot after the referenced offering. It expressly notes the manager-client relationship: Heights Capital Management, Inc. serves as investment manager to CVI Investments, Inc.
Key dependencies include the Limited Power of Attorney and the accuracy of the Prospectus Supplement's 13,526,233 Shares outstanding figure. Subsequent filings would show any changes in holdings or voting power.
Filing aligns with Schedule 13G passive/reporting conventions.
The statement follows Schedule 13G formats by reporting amount beneficially owned, percent of class (5.5%), and the voting/dispositive power breakdown. It attaches a Limited Power of Attorney and Joint Filing Agreement to support authority to file.
Material actionability is limited: the filing is informational under securities rules and does not indicate planned transactions. Future Form 13D/4 filings would be required if the purpose or control intent changes.
Key Figures
Key Terms
beneficially owned regulatory
Limited Power of Attorney legal
Schedule 13G regulatory
FAQ
What stake does CVI Investments report in CervoMed (CRVO)?
What documents accompany the Schedule 13G for CRVO?
Does this filing indicate an intent to acquire control of CervoMed?
AI-generated analysis. How Rhea-AI works. Not financial advice.